A Efficacy and Safety Study of Nasal Prongs With Proprietary Surface Coating Aiming to Reduce Bacterial Colonization

Exclusion Criteria

• •1. Pregnant or nursing women.
• •2. Subjects who are active smokers or using snuff.
• •3. Subjects currently suffering from a common cold, sinusitis, allergies or sleep apnea.
• •4. Subjects suffering from and/or subjects that have experienced nosebleed within 1 month prior to entering the study.
• •5. Subjects using and/or subjects that have used oral or topical antibiotics within 2 weeks prior to entering the study.
• •6. Subjects using and/or subjects that have used oral or topical anti-inflammatory drugs within 1 week prior to entering the study.
• •7. Subjects participating in any other clinical study.
• •8. Subjects diagnosed with any type of skin infection (bacterial, viral or fungal) or inflammatory skin disease including psoriasis, eczema or severe acne
• •9. Subjects diagnosed with any type disease affecting mucus membranes.
• •10. Subjects suffering from any other condition or symptoms preventing the subject from entering the study, according to the investigator´s judgment.
• •11. Subjects who have a lesion (including lymphadenopathy), dysaesthesia, previous surgery or abnormal anatomy at the Nasal Prong target site
• •12. Any subject that according to the Declaration of Helsinki is deemed unsuitable for study enrolment.